報價延遲最少15分鐘:2025/02/24 15:23 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.86 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.01/--
|
|
企業價值
117.60M
|
| 資產負債 |
|
每股賬面淨值
-0.02
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/02/24 15:23 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tract. |